Pr François Ghiringhelli

Specialty

Oncologist, digestive expert

Hospital

Centre Georges-François Leclerc (Dijon)

Latest articles

• Targeting Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer: Beyond PD-1/PD-L1 Monoclonal Antibodies. (Mar 6, 2025)
• FOLFIRINOX-3 plus bevacizumab (bFOLFIRINOX3) in chemo-refractory metastatic colorectal cancer: a multicenter phase II trial. (Mar 1, 2025)
• Mimicry-based strategy between human and commensal antigens for the development of a new family of immune therapies for cancer. (Feb 20, 2025)
• Safety and efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial. (Jan 17, 2025)
• Deep learning uncovers histological patterns of YAP1/TEAD activity related to disease aggressiveness in cancer patients. (Dec 20, 2024)